Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Consolidated Net Income rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13432.12%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • Per Keros Therapeutics' latest filing, its Consolidated Net Income stood at -$7.3 million for Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Consolidated Net Income registered a high of $148.5 million during Q1 2025, and its lowest value of -$53.0 million during Q3 2024.
  • In the last 5 years, Keros Therapeutics' Consolidated Net Income had a median value of -$29.7 million in 2022 and averaged -$21.6 million.
  • As far as peak fluctuations go, Keros Therapeutics' Consolidated Net Income plummeted by 32821.33% in 2022, and later soared by 44432.2% in 2025.
  • Over the past 5 years, Keros Therapeutics' Consolidated Net Income (Quarter) stood at -$6.9 million in 2021, then crashed by 328.21% to -$29.7 million in 2022, then plummeted by 56.32% to -$46.5 million in 2023, then rose by 0.92% to -$46.0 million in 2024, then surged by 84.18% to -$7.3 million in 2025.
  • Its Consolidated Net Income was -$7.3 million in Q3 2025, compared to -$30.7 million in Q2 2025 and $148.5 million in Q1 2025.